Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ThromboGenics Appoints Dr David Guyer to its Board of Directors

Published: Monday, December 23, 2013
Last Updated: Sunday, December 22, 2013
Bookmark and Share
Dr Guyer is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation.

ThromboGenics NV has announced the appointment of Dr David Guyer to its Board of Directors.

Dr Guyer M.D. is a long standing member of the US retina community and is currently the Co-Founder and Chief Executive Officer of Ophthotech Corporation and also serves as Chairman of its board of directors.

Ophthotech Corporation is a public biopharmaceutical company focusing on discovering, developing and commercializing first-in-class therapies for the treatment of major ophthalmic diseases.

Ophthotech’s lead compound Fovista (previously known as E10030) is being evaluated in a Phase III trial for use in combination with anti-VEGF therapy for the treatment of patients with wet AMD. Ophthotech listed on Nasdaq in September 2013, raising $192 million in its IPO.

Dr. Guyer is also on the Boards of Allocure and Panoptica.

Dr.Guyer co-founded and served as CEO and a Director of Eyetech Pharmaceuticals, Inc., where he led the company through private, public and corporate financings, and oversaw the rapid development and successful commercialization of Macugen® (pegaptanib sodium), the first FDA-approved anti-VEGF pharmacological treatment for the treatment of wet AMD. Eyetech was acquired by OSI Pharmaceuticals Inc for $935 million in 2005.

Staf Van Reet, the Chairman of ThromboGenics commenting on today’s announcement said, “I am delighted to welcome David to the Board. His decades of success in the ophthalmology space both in drug development and commercialization, particularly in the US, will be extremely valuable to ThromboGenics. We are continuing to maximize the potential of JETREA® for the treatment of symptomatic VMA and further develop our emerging portfolio of therapies for the treatment of diabetes-related retinal diseases.”

Dr Guyer has also had a successful career in academic medicine as Professor and Chairman of the Department of Ophthalmology at New York University School of Medicine. Dr. Guyer received his Bachelor of Science (B.S.) degree from Yale College summa cum laude and his medical degree (M.D.) from Johns Hopkins Medical School. He completed his ophthalmology residency at Wilmer Ophthalmological Institute at Johns Hopkins Hospital and a retinal fellowship at the Massachusetts Eye and Ear Infirmary at Harvard Medical School.

Dr David Guyer, commenting on his appointment, said, “ThromboGenics has made significant progress in recent years, leading to the introduction of JETREA® in the US early in 2013. I am happy to be joining the board of this dynamic company as it works to create a new treatment paradigm for patients with early stage symptomatic VMA.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ThromboGenics Appoints Dominique Vanfleteren as New CFO
Dominique has over 25 years of experience in senior finance, operational, control and reporting roles.
Saturday, January 17, 2015
ThromboGenics’ JETREA® Gains First Asian Approval in Malaysia
JETREA® (ocriplasmin) has been approved for the treatment of adults with vitreomacular traction.
Tuesday, April 22, 2014
ThromboGenics’ JETREA® Receives Positive Common Drug Review in Canada
CDR provides formulary listing recommendations to Canada’s publicly funded drug plans.
Monday, December 30, 2013
ThromboGenics’ Founder Prof Desire Collen Retiring as Chairman
Dr Staf Van Reet appointed as new Chairman of the Board.
Monday, December 09, 2013
ThromboGenics’ JETREA® Available in Germany Public and Private Market
Company could receive a further €210 million in milestones plus significant royalties.
Friday, May 03, 2013
ThromboGenics Receives Positive CHMP Opinion for JETREA®
Positive opinion clears the way for the potential EMA approval of JETREA® as the first pharmacological option for the treatment of VMT, including when associated with macular hole of diameter less than or equal to 400 microns.
Wednesday, April 24, 2013
ThromboGenics’ JETREA® Granted EU Approval for VMT
EU approval of JETREA® triggers a €45 million milestone payment from Alcon.
Monday, April 15, 2013
JETREA® Selected for Single Technology Appraisal by UK’s NICE
The outcome of the STA is expected later in 2013.
Monday, March 25, 2013
ThromboGenics Announces Business Update and 2012 Full-Year Results
Transformational 2012 delivers euro 30 million in net profit.
Tuesday, March 19, 2013
Scientific News
Combining Chemotherapy With Immune-Blocking Drug Could Stop Cancer Growing Back
Giving patients a drug that blocks part of the immune system from going into overdrive might help prevent cancer coming back in some people.
Researchers Pioneer Use of Capsules to Save Materials
Wax capsule delivery systems can simplify a wide range of chemistry transformations.
Photoredox Catalyst Unlocks New Pathways for Nickel Chemistry
Using a light-activated catalyst, researchers have unlocked a new pathway in nickel chemistry to construct carbon-oxygen (C-O) bonds that would be highly valuable to pharmaceutical and agrochemical industries.
Scientists Determine How Antibiotic Gains Cancer-Killing Sulfur Atoms
In a discovery with implications for future drug design scientists have shown an unprecedented mechanism for how a natural antibiotic with antitumor properties incorporates sulfur into its molecular structure, an essential ingredient of its antitumor activity.
Familiar Drugs May Block Ebola Virus Infection
A well-known class of molecules, many of which are already in use therapeutically, may be able to block the Ebola virus’s entry into cells and halt the disease in its tracks, according to researchers at the University of Illinois at Chicago.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Common Class of ‘Channel Blocking’ Drugs May Find a Role in Cancer Therapy
Discoveries in fruit flies prompt unusual treatment of patient with metastatic disease.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
Scientists Make Strides in Therapy Preventing Addiction Relapse
Single Injection of Drug Candidate Prevents Meth Relapse in Animal Models.
New Clot-Busting Treatments Target Number One Killer
Australian researchers funded by the National Heart Foundation are a step closer to a safer and more effective way to treat heart attack and stroke via nanotechnology.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!